ここから本文です

AACR2018 proceedingsにステルス テロメライシンでてますね。アメリカでどう評価されるか楽しみですね。
3714 Stealth liposomes encapsulating plasmid DNA of telomerase specific oncolytic adenovirus. Yoshihiko Kakiuchi. Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Background: Oncolytic virotherapy has the potential to become the next breakthrough in cancer therapy. We previously established a telomerase-specific oncolytic adenovirus (Telomelysin), which is controlled to replicate and induce oncolytic cell death selectively in tumor cells, and its safety for humans was proven in the phase I clinical trial performed in the USA. While oncolytic adenoviruses have promising antitumor effects, the application is basically limited to local administration because of non-specific trapping in the liver and immune elimination after systemic delivery. Liposomes are among the most common nanoparticles used as drug carriers, and liposome-encapsulated therapeutic agents enhance ・・・